3 March 2025 in eLife preprints
Antimicrobial peptides (AMPs) are attractive candidates to combat antibiotic resistance for their capability to target bio-membranes and restrict a wide range of pathogens. It is a daunting challenge to discover novel AMPs due to their sparse distributions in a vast peptide universe, especially for peptides that demonstrate potencies for both bacterial membranes and viral envelopes. Here we establish a de novo AMP design framework by bridging a deep generative module and a graph-encoding activity regressor. The generative module learns hidden ‘grammars’ of AMP features and produces candidates sequentially pass antimicrobial predictor and antiviral classifiers. We discover 16 bifunctional AMPs and experimentally validated their abilities to inhibit a spectrum of pathogens in vitro and in animal models. Notably, P076 is a highly potent bactericide with the minimal inhibitory concentration of 0.21 μM against multidrug-resistant A. baumannii, while P002 broadly inhibits five enveloped viruses. Our study provides feasible means to uncover sequences that simultaneously encode antimicrobial and antiviral activities, thus bolstering the function spectra of AMPs to combat a wide range of drug-resistant infections.
15 January 2025 in bioRxiv
In the post-antibiotic era, antimicrobial peptides (AMPs) serve as ideal drug candidates for their lower likelihood of inducing resistance. Computational models offer an efficient way to design novel AMPs. However, current optimization and generation approaches are tailored for different application scenarios. To address this challenge, we propose a novel AMP design model named AMPainter. Based on deep reinforcement learning, AMPainter integrates both optimization and generation tasks in a unified framework. We apply AM-Painter to three types of peptides, including known AMPs, signal peptides (SPs), and random sequences. AMPainter outperforms ten related models in enhancing the activity of known AMPs, and evolves effective AMPs from membrane-active SPs with a success rate of 80%. Furthermore, several de novo designed AMPs from random sequences are validated along with their evolutionary paths. Therefore, AMPainter contributes to paint antimicrobial potency to diverse peptides, assisting in expanding the AMP sequence space and discovering novel antimicrobial agents.
24 February 2024 in bioRxiv
Antimicrobial peptides (AMPs) are attractive candidates to combat antibiotic resistance for their capability to target bio-membranes and restrict a wide range of pathogens. It is a daunting challenge to discover novel AMPs due to their sparse distributions in a vast peptide universe, especially for peptides that demonstrate potencies for both bacterial membranes and viral envelopes. Here we establish a de novo AMP design framework by bridging a deep generative module and a graph-encoding activity regressor. The generative module learns hidden ‘grammars’ of AMP features and produces candidates sequentially pass antimicrobial predictor and antiviral classifiers. We discover 16 bifunctional AMPs and experimentally validated their abilities to inhibit a spectrum of pathogens in vitro and in animal models. Notably, P076 is a highly potent bactericide with the minimal inhibitory concentration of 0.21 μM against multidrug-resistant A. baumannii , while P002 broadly inhibits five enveloped viruses. Our study provides feasible means to uncover sequences that simultaneously encode antimicrobial and antiviral activities, thus bolstering the function spectra of AMPs to combat a wide range of drug-resistant infections.
3 February 2026 in bioRxiv
Motivation: The membrane-lytic mechanism of antimicrobial peptides (AMPs) is often overlooked during their in silico discovery process, largely due to the lack of a suitable metric for the membrane-binding propensity of peptides. Previously, we proposed a characteristic called membrane contact probability (MCP) and applied it to the identification of membrane proteins and membrane-lytic AMPs. However, previous MCP predictors were not trained on short peptides targeting bacterial membranes, which may result in unsatisfactory performance for peptide studies. Results: In this study, we present PepMCP, a peptide-tailored model for predicting MCP values of short peptides. We collected more than 500 membrane-lytic AMPs from the literature, conducted coarse-grained molecular dynamics (MD) simulations for these AMPs, and extracted their residue MCP labels from MD trajectories to train PepMCP. PepMCP employs the GraphSAGE framework to address this node regression task, encoding each peptide sequence as a graph with 4-hop edges. PepMCP achieved a Pearson correlation coefficient of 0. 883 and an RMSE of 0. 123 on the node-level test set. It can recognize membrane-lytic AMPs with the predicted MCP values for each sequence, thereby facilitating mechanism-driven AMP discovery. Additionally, we provide a database, MemAMPdb, which includes the membrane-lytic AMPs, as well as the PepMCP web server for easy access. Availability and Implementation: The code and data are available at https://github.com/ComputBiophys/PepMCP.